Toxicology

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Retrieved on: 
Thursday, July 28, 2022
Online, Severe acute respiratory syndrome coronavirus 2, University, College of Medicine, GLOBE, Omicron, Pharmacology, Southwestern United States, College, McGill, U.S. Securities and Exchange Commission, Drug discovery, Doctor of Philosophy, Student, Medicine, Neurodegeneration, CEO, SEC, Research, Addiction, Nursing school, Toxicology, Squamous cell carcinoma, Immune system, Safety, COVID-19, Degenerative disease, Vaccine, NASDAQ, General Hospital, Cancer, Pancreatic cancer, Company, Pharmacokinetics, Pain, Faculty, Measles, Growth, Risk, Contract, Disease, Combined small-cell lung carcinoma, Public health, Breast cancer, Pharmaceutical industry, Pharmacy

At the University of Arizona Health Sciences, Gregory Thatcher, PhD, a professor of pharmacology and toxicology and the R. Ken and Donna Coit Endowed Chair of Drug Discovery, is leading the research effort that is progressing as planned.

Key Points: 
  • At the University of Arizona Health Sciences, Gregory Thatcher, PhD, a professor of pharmacology and toxicology and the R. Ken and Donna Coit Endowed Chair of Drug Discovery, is leading the research effort that is progressing as planned.
  • Located on campuses in Tucson, Phoenix and Gilbert, Arizona, the University of Arizona Health Sciences is one of the top-ranked academic medical centers in the southwestern United States.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.
  • Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update

Retrieved on: 
Thursday, July 28, 2022
Time, Inflammation, Skin, Capsule, Psoriasis, MHRA, Degenerative disease, Institute of Cancer Research, AIM, Biomarker, CRO, Toxicology, CTA, Patent, GMP, Safety, COVID-19, JAK1, Cancer, Q&A, Clinical trial, Company, Patient, T-ALL, The Institute, GlaxoSmithKline, Medicines and Healthcare products Regulatory Agency, TYK2, Survival, CHEK1, Autoimmune disease, Pharmaceutical industry, Vaccine, IMC

Sareum also provides a broader update on operational activities and pipeline progress.

Key Points: 
  • Sareum also provides a broader update on operational activities and pipeline progress.
  • Preclinical development activities required to apply for the CTA have been successfully concluded and, consistent with the Companys clinical development plan, an application for a CTA has now been filed.
  • TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis.
  • Sareum, working alongside a specialist contract research organisation (CRO), has designed a Phase 1a/b clinical trial with SDC-1801 in healthy subjects and psoriasis patients.

Novartis and UC Berkeley Extend Alliance to Tackle 'Undruggable' Disease Targets and Discover New Therapeutic Modalities

Retrieved on: 
Thursday, July 28, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Proteomics, Goal, Sale, NIBR, University, TPD, University of California, Berkeley, Physician, Protein, Regulation, Industry, U.S. Securities and Exchange Commission, Forward-looking statement, Research, Cell biology, Government, Drug discovery, Biomedical Research, Associate, Private Securities Litigation Reform Act, Institute, Safety, Novartis Institute for Tropical Diseases, UC, Maimone, Cancer, Clinical trial, Technology, Publication, Disease, Science, Patient, Form 20-F, Therapy, Lists of diseases, Nutritional science, Toxicology, Pharmaceutical industry, Fine chemical, Chemistry, Novartis

Most proteins do not possess well-defined binding pockets or ligandable hotspots that can be pharmacologically and functionally targeted for therapeutic benefit.

Key Points: 
  • Most proteins do not possess well-defined binding pockets or ligandable hotspots that can be pharmacologically and functionally targeted for therapeutic benefit.
  • Tackling these undruggable proteins requires the development of innovative technologies for ligand discovery and the discovery of novel therapeutic modalities to functionally manipulate these intractable proteins for therapeutic benefit.
  • This research collaboration allows UC Berkeley scientists to work with their scientific peers at Novartis Institutes for BioMedical Research (NIBR) to find new cures for debilitating illnesses.
  • The second phase of the research collaboration is the Novartis-Berkeley Translational Chemical Biology Institute, and is based at UC Berkeley.

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Retrieved on: 
Thursday, July 28, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Novartis, Lists of diseases, DUB, Gene, Novartis Institute for Tropical Diseases, Doctor of Philosophy, Nutritional science, CFTR, Protein, Cell death, Research, General partnership, Chimera, Cancer, Technology, Deubiquitinating enzyme, Proximity, Berkeley, Associate professor, Industry, Biomedical Research, Health, Howard Hughes Medical Institute, Princeton University Department of Chemistry, UC, Nature Chemical Biology, Science, Therapy, OTUB1, Chemical biology, University, GV, University of California, Berkeley, Cell biology, Drug discovery, Associate, UCSF, WEE1, Patient, Department, Cystic fibrosis, Toxicology, Pharmaceutical industry, Vaccine, Fine chemical, Management, Microscope, Chemistry, Series

Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.

Key Points: 
  • Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
  • Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
  • In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation.
  • Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Retrieved on: 
Wednesday, July 27, 2022
Swelling, GLOBE, Allodynia, CEO, Research, Hyperalgesia, Toxicology, Private Securities Litigation Reform Act, Patent, News, PTSD, Company, Patient, Lists of diseases, Therapy, Rheumatoid arthritis, Fine chemical, Pharmaceutical industry, Fibromyalgia, Ketamine

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Key Points: 
  • Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system
    ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc .
  • (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.
  • These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharmas partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.
  • Eric Weisblum, CEO of Silo Pharma, commented, These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction.

Inotiv, Inc. Continues to Expand Genetic Toxicology Offering with Support of GLP Assays at Rockville, MD, Location

Retrieved on: 
Tuesday, July 26, 2022
Goal, Pathology, Acquisition, GLOBE, Genomics, Industry, U.S. Securities and Exchange Commission, Research, Toxicology, Marketing, Safety, NASDAQ, Cytogenetics, Drug development, Technology, Company, Good laboratory practice, Therapy, Efficiency, Program, LLC, Pharmaceutical industry, Risk management

Since acquiring key genetic toxicology assets from MilliporeSigmas BioReliance portfolio in July 2021, the Company has been hiring and investing in validating and further developing those assets to offer clients critical genetic toxicology services to support their drug development goals.

Key Points: 
  • Since acquiring key genetic toxicology assets from MilliporeSigmas BioReliance portfolio in July 2021, the Company has been hiring and investing in validating and further developing those assets to offer clients critical genetic toxicology services to support their drug development goals.
  • With the acquisition of North Carolina-based Integrated Laboratory Systems, LLC ( now Inotiv RTP) in January 2022, the Company further expanded its GLP safety assessment offerings for in vivo and in vitro general and genetic toxicology services, including the addition of significant pathology and toxicology expertise, as well as adding genomics, bioinformatics and computational toxicology services.
  • Our genetic toxicology service offering is expanding in order to meet growing demand and we continue to develop our program across these two sites to help drive research and innovation for our clients, said David Allen, Ph.D., Vice President, Inotiv RTP.
  • Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services.

Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Tuesday, July 26, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Clinical Trials, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sale, Â, ISEE, OCT, Silicon Valley Bank, Retinal, Safety, Clinical trial, Company, Security (finance), International, Investor, Injection, Research, U.S. Securities and Exchange Commission, Synthetic control method, Annual general meeting, Toxicology, C5, Technology, CNVM, D, Society, IND, American Academy, Physician, Food, STAR, COVID-19, Organization, European Medicines Agency, FDA, Nasdaq, Retina, IRDS, Endophthalmitis, Hercules, SVB, Forward-looking statement, American Academy of Ophthalmology, Geographic atrophy, AMD, Private Securities Litigation Reform Act, MNV, Inflammation, Patient, FAF, Pharmaceutical industry, Tutoring, Ophthalmology, MD

IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update.
  • The Company expects topline data from the GATHER2 clinical trial to be available in September 2022.
  • Patient retention for the GATHER2 clinical trial, as measured by the injection fidelity rate, continues to exceed the Companys expectations.
  • Iveric Bio will host a conference call/webcast to discuss the Companys financial and operating results and provide a business update.

Thermo Fisher Scientific Showcases New Clinical and Research Lab Solutions at AACC 2022

Retrieved on: 
Monday, July 25, 2022
Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Genetics, Health Technology, Science, COVID-19, Biotechnology, Medical Supplies, Practice Management, Health, Transfer, Association, MAS, PPD, Diagnosis, Diversified Pharmaceutical Services, Thermo Fisher Scientific, Laboratory, U.S. FDA, Industry, Health, Elia, Scleroderma, Research, Genetics, Solution, Toxicology, Patheon, LC-MS/MS, TLA, American Association, Tsing Ma Control Area, COVID-19, Mindful Scientific Inc., Kingfisher, EUA, Fisher Scientific, Applied Biosystems, Infection, Â, AACC, Science, Patient, COVID, Ortho, FDA, Control, PCR, Invitrogen, Automation, Emergency Use Authorization, Medical device, Animal, Pharmaceutical industry

AACC 2022 Thermo Fisher Scientific Inc., the world leader in serving science, is showcasing innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics.

Key Points: 
  • AACC 2022 Thermo Fisher Scientific Inc., the world leader in serving science, is showcasing innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics.
  • During the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022), being held at the McCormick Place Convention Center in Chicago, July 2428, Thermo Fisher is exhibiting within booth #1413.
  • ***The Thermo Scientific Cascadion SM Clinical Analyzer, the Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay and the Thermo Scientific EliA RNA Pol III and EliA Rib-P are For In Vitro Diagnostic Use.
  • For more information on all the Thermo Fisher products and solutions exhibited at AACC 2022, please visit: thermofisher.com/aacc .

Global Rat Model Market Research 2022-2027: Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area - ResearchAndMarkets.com

Retrieved on: 
Friday, July 22, 2022
Health, Other Health, Transfer, SWOT, Investment, Others, COVID-19, Market development, Environmental impact of pharmaceuticals and personal care products, Microinjection, Industry, Genetic testing, Risk, Quarantine, Inflammation, USD, Ansoff Matrix, Geography, CAGR, Clinical trial, Horizon Discovery, Taconic Biosciences, Children's Environmental Exposure Research Study, Neurology, Rat, Emotion, Competitive analysis, Diabetes, Impact, Growth, Pharmaceutical industry, Retail, Risk management, Trapping, Cryopreservation, Cages, Envigo, Technology, CRISPR, Toxicology, Breeding

The "Global Rat Model Market (2022-2027) by Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Rat Model Market (2022-2027) by Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Market dynamics are forces that impact the prices and behaviors of the Global Rat Model Market stakeholders.
  • The report analyses the Global Rat Model Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • By Clinical Trials & Research, the market is classified into Clinical Trials, and Research Studies.

Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials

Retrieved on: 
Friday, July 22, 2022
Novartis, Diagnosis, Atezolizumab, Lipid, Ipilimumab, CTA, Cell, EP4, Clinical trial, AbbVie, Immunotherapy, Hope, Cancer Research UK, Drug development, Neurocrine Biosciences, Infection, Environment, Research, Pembrolizumab, Toxicology, Head, MSS, Cancer, Temozolomide, Takeda, Technology, Heart, Nivolumab, AstraZeneca, Colorectal cancer, Nursing, DNA, Neoplasm, GLOBE, GPCR, Tissue, Twitter, Government, Immune system, Cancer research, Conference, GLP, GSK, Tokyo Stock Exchange, Neck, Survival, Neurology, Ovarian cancer, IMP, Inflammation, Prostate cancer, Gastroenterology, Prostaglandin, Therapy, PGE2, Patient, Brain, Gq alpha subunit, Pharmaceutical industry, Medical imaging, Dietary supplement, Medical device, Fine chemical, Pfizer, Genentech, Facebook

"We are therefore thrilled to be partnering with Sosei Heptares to bring their novel immunotherapy candidate into human trials.

Key Points: 
  • "We are therefore thrilled to be partnering with Sosei Heptares to bring their novel immunotherapy candidate into human trials.
  • Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, commented: We are extremely pleased to collaborate with Cancer Research UK to advance HTL0039732 into Phase I/IIa clinical trials and take a step towards bringing new treatments to cancer patients.
  • Cancer Research UK receives no funding from the UK government for its life-saving research.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.